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War against disease without violence to clinical trial participants? 
Roger Jeffery 
‘War’ discourses characterise increasing areas of modern life, from the wars on illegal drugs, 
on terrorism, on racism and on illegal immigration, and wars on disease are also common-
place. Other martial metaphors include the use of patients as ‘targets’ or seeing pharmaceuticals 
as ‘golden bullets’ in the treatment of disease. In India since 2005, this kind of approach and 
its implications for the management of clinical trials of potential new drugs has raised serious 
concerns amongst regulators, parliamentarians, and civil society organisations. Clinical trials 
raise some thorny ethical issues everywhere, more problematically in highly inegalitarian 
societies like India that are rapidly developing. Sometimes the ‘ends’ for which the trial is 
being carried out are challenged; more often, the ‘means’ by which trials are achieved are 
accused of putting trial participants at unwarranted risks. Taking ‘informed consent’ from trial 
participants may neither inform nor ensure voluntary consent, but rather becomes a way of 
protecting researchers. Responsibility for ‘serious adverse events’ (including death) affecting 
those on a trial is often distributed and avoided by all stake-holders. Continuity of care – in 
trials involving chronic illnesses – is rarely provided, so that patients whose lives have been 
eased by new treatments may find them suddenly unavailable except at high cost. This chapter 
asks if the concepts of ‘structural violence’ (with its associated notion of ‘structural coercion’) 
or approaches drawing on Bourdieu’s concept of ‘symbolic violence’ offer a useful handle on 
such events. 
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Introduction 
In 2006, the Bill and Melinda Gates Foundation granted PATH, a Seattle-based NGO, US 
$27.8 million to conduct research in India, Peru, Uganda, and Vietnam ‘to gather the evidence 
countries need to make informed decisions about how to introduce a vaccine’ against two types 
of Human Papilloma Virus (HPV), which is a precursor to some kinds of cervical cancer (see 
also (McCoy et al. 2009).1 In partnership with the Indian Council of Medical Research (ICMR), 
PATH carried out post-licensure observational studies in two Indian States, Andhra Pradesh 
and Gujarat. No biomedical outcomes were researched; no blood or other samples were drawn; 
and no new therapies were tested. The safety and efficacy of these vaccines had already been 
assessed in many clinical trials and endorsed by international and national regulatory agencies. 
PATH and the ICMR took ethical clearance in India and the USA, and involved the 
governments of the two States in delivery of the vaccine to selected groups of adolescent girls. 
Starting in 2009, they vaccinated over 23,000 girls. Despite all these precautions, in 2010, after 
a huge media outcry, the studies were suspended. Protests spiralled, and enquiries were 
instigated by the Indian Parliament and its Supreme Court.  
The Supreme Court responded to a Public Interest Litigation petition filed in February 2012, 
which sought to halt the conduct of all clinical trials in India for new products.  It alleged that 
weak regulatory controls on the conduct of clinical trials, combined with their poor 
enforcement, had contributed to an unacceptable number of deaths – estimated at 2,262 clinical 
trial participants in 2006–11 – and other adverse events. Furthermore, many trials were for 
drugs and devices that would not be sold or marketed in India, and would thus not advance 
Indian healthcare. In an internationally unprecedented interim ruling on 30 September 2013, 
the Supreme Court of India halted the approval by the Drugs Controller General-India (DGCI) 
of new clinical trials, pending a more effective review and monitoring system. Reports by a 
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joint committee of the two Indian houses of Parliament also reviewed the PATH trial, and the 
operations of the regulatory body, the Central Drugs Standards Control Organisation 
(CDSCO), making sweeping criticisms (Parliament of India 2012; Parliament of India 2013). 
This chapter considers the utility of concepts of violence and non-violence in understanding 
how such apparently safe and desirable health interventions, initiated with benign intent, could 
have become the cause of so much ferment. After briefly discussing the introduction of the 
assemblages that constitute clinical trials globally in the 21st century (including the origins and 
key features of the ethical codes drawn upon in assessing and approving them), I present some 
examples of the main problems that have arisen in India. I then turn to a critical discussion of 
the dominant approaches to the human rights challenges that these Indian clinical trials 
exemplify, through the lens of ‘structural violence,’ in non-Marxist and Marxist variants and 
then Bourdieu’s concept of symbolic violence. In conclusion, I will assess the utility of these 
approaches not only for understanding the key problems but also for assessing public policy to 
mitigate them. 
Global Ethics, Global Trials 
Bio-medicine – the versions of medical practice with their origins and bases predominantly 
within Europe, North America and Japan, or the Global North – has been transformed since 
the end of the Second World War. Nowhere is this more obvious than in how new medicines 
are assessed and introduced into the ‘armoury’ which doctors can access. The organised, 
systematic collection of data on a large scale about the uses and dangers of potential medicines, 
barely visible before the 1950s, now operates on a global scale. Ethical codes to prevent human 
rights abuses were developed in response to the horrifying evidence of how camp doctors in 
Nazi Germany coerced inmates into dangerous, painful and often deadly experiments. Legal 
frameworks, medical and para-medical training programmes, and the activities of medical 
associations now embody these codes.  
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Fischer (2006) usefully lists the history of the development of the Nuremberg Code, the World 
Medical Association’s Helsinki Declarations, and the Good Clinical Practice (GCP) guidelines 
of the International Conference on Harmonisation (ICH). The ICH-GCP guidelines have come 
to dominate international trials; they focus on procedures, whereas the Helsinki Declarations 
include a concern with moral principles (Goldacre 2012: 118-119). For example, the Helsinki 
Declaration states that research must benefit the population within which it is being trialled, 
whereas the ICH-GCP is silent on this point. One aspect of this potential benefit – the post-trial 
availability of medicines – is a salient issue if the trial is successful, chronic illnesses are 
involved, and (as in India) there is no effective National Health Service. In one study, nearly 
half of the successful drugs trialled in 2010 were not licensed for sale in India (Limaye et al. 
2015: 2-4).  
For India, the ICMR produced “Ethical Guidelines for Biomedical Research on Human 
Participants” in 2006, reflecting most international standards but specifying more protection of 
vulnerable populations and minorities, the compulsory registration of all new clinical trials in 
the Clinical Trials Registry of India (from 2009) and the registration of ethics committees (Burt 
et al. 2014). Yet the enforcement mechanisms are opaque, and the ICMR itself breached its 
own regulations as a co-sponsor of the PATH study. 
How to provide a moral compass for trial managers has become the subject of intense debates 
amongst ethicists and medical personnel, who have offered various solutions to the main 
concerns surrounding medical experiments: with informed consent; with the choice and control 
of interventions (whether, for example, to use a placebo or current best practice); with whether 
special procedures are necessary for ‘vulnerable’ sub-groups of a population such as children; 
and with the scale and form of compensation for any adverse events that result from 
involvement in a trial. 
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Only some ‘clinical trials’ offer suffering patients the opportunity to try out new – and 
potentially life-saving – drugs, or vaccines that might protect them from life-threatening 
diseases.2 Drug or vaccine researches might now start with computer simulations of molecules 
and their likely effects followed by tests on animals, before reaching Phase I – sometimes called 
‘first in human’ – trials on healthy volunteers. Phase II trials expand the trial to a larger group 
of patients with the relevant condition, to test dose levels, efficacy and side-effects. Phase III 
trials, increasingly double-blind, randomised control trials on many patients, in multiple sites, 
offer the drugs to patients with the disease in question. ‘Double-blind’ trials are ones in which 
neither the patients nor those treating them know if they are receiving the drug being tested or 
an alternative, an inert substance – a placebo – or one or more versions of current good practice. 
Patients are recruited according to very specific rules, set out in the trial protocol, which is set 
by the sponsor of the trial, usually a large pharmaceuticals company based in north America, 
Europa or Japan (Sariola et al. 2015).  
These global assemblages of clinical trials involve expectations of, and aspirations to, universal 
standards of design, method, reliability, validity, and reporting of results – as well as of ethical 
procedures. The sponsors try to impose their own protocols, rules and guidelines, but inevitably 
lose a degree of oversight as they negotiate with local partners for trial approval, recruitment 
of patients etc. The local teams co-construct – from very unequal starting points – the 
practicalities of any particular research project. Local 'principal investigators' are responsible 
for communicating the risks and hazards that feature prominently as part of these processes. 
But once trial sponsorship and management is out-sourced in this way, responsibilities are hard 
to pin down (Glickman et al. 2009). For example, in the Oasis-6 cardiac trials in Bhopal, 
discussed below, a French company developed the drug, a British one sponsored the trial, and 
an Indian CRO managed the trial in India; the trial co-ordinator was based in Canada (Lakhani 
2011).  
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Clinical trial assemblages are the ‘cutting edge’ in a process of de-territorialisation which bring 
global procedures into everyday settings [hospitals, laboratories etc.] and attempt to render 
them coeval and continuous with others around the globe. Furthermore, clinical trials manage 
trial subjects and induct them into the global laboratory that such procedures represent. Trials 
are gatekeepers to a global modernity for members of these assemblages, who regulate access 
to different regimes of care but also to new temporalities [via the research process], new spaces 
[in the clinic/ hospital as laboratory], and most important, futures [as biological citizens (Rose 
and Novas 2005), biomedical citizens (Petryna 2005), therapeutic citizens (Nguyen 2005) 
pharmaceutical citizens (Ecks 2005) or bioethical citizens (Simpson et al. 2015)].   
The ethical issues (or the kind of ‘violence’) vary between phase I (small numbers of healthy 
volunteers) and phase III (large numbers of sick people). But the context within which the trials 
take place also matters. Between the 1990s and the 2010s, clinical trials activity has shifted 
significantly, to recruit participants from many countries beyond Europe and North America. 
Since 2005, India has been included as an option for ‘multi-sited global clinical trials’ that 
recruit participants from many different sites, often spread over many countries, in order to 
speed up recruitment and to reduce costs.  
India in Global Trials 
Until 2005 clinical trials could not be conducted in India in the same phase concurrently with 
trials elsewhere, leading to a ‘phase-lag. In 2005 the law governing clinical trials was amended 
to allow concurrent trials of drugs and devices with trial sites abroad, except for Phase I. Until 
2011, Phase III trials were the most numerous in India (Borkar, Jacob and Ravindran 2011; 
Ravindran and Nikarge 2010); after that, the numbers of Phase I trials have matched those of 
Phase III. About half of these studies involved foreign sponsorship. Different sources give very 
different indicators of the proportion of globalised trials that include sites in India, but they 
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agree that from 2005 to 2010 the numbers grew rapidly, declining thereafter (Burt et al. 2014). 
In addition to the global multi-sited trials, leading Indian pharmaceuticals companies have 
increased the numbers of trials they carry out (Malhotra 2008). Nonetheless, India accounted 
for only a small proportion of all registered global multi-sited trials in the peak year.  
As far as Indian doctors and business, clinical research organisations, hospitals and the 
Government of India’s Department of Bio-Technology are concerned, however, clinical trials 
are rarely described as offering benefits to the Indian population in terms of access to new and 
better drugs (Bajpai 2013). Rather, global clinical trials represent a new set of financial and 
employment opportunities. The Indian trade press regularly repeats claims of the financial 
benefits to foreign innovator companies and contract research organisations of the large 
clinically-naïve population in India, the availability of high quality hospitals and researchers 
speaking good English, and the low costs – supposedly around half those for equivalent trials 
in the USA (Yee 2012: 397). Companies may also outsource trials in order to avoid the close 
surveillance of the FDA, EMA and other international agencies, which have much less 
information on trials conducted somewhere like India. This situation is changing, as these 
agencies demand more information about the standards being followed in outsourced trials. 
Authors based at the US FDA have produced a long list of the factors that need to be taken into 
account when designing multi-regional trials – highlighting the large differences between India 
and the main centres of such trials in North America, Western and Eastern Europe. Rather than 
acknowledge these differences, and find ways to adapt to local circumstances, however, FDA 
officials attempt to remove them: ‘It is therefore critical to anticipate and decrease, to the extent 
possible, variability by using precise definitions, similar treatment standards, concomitant 
treatments, and so on’ (Khin et al. 2013).  
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When global clinical trials arrived in India, the procedures for regulating them were slow to 
react. CDSCO and the state-level equivalents had too few staff to cope, and they were – in 
general – inadequately trained. In India, the number of staff in the state FDAs and in CDSCO 
are still far too few for their main tasks of regulating production and distribution of drugs, let 
alone taking on board assessing clinical trials (Kadam et al. 2016). To begin with, many of 
those involved in running and regulating clinical trials did not understand what they were 
‘about’. In the industry’s self-representations, clinical trials are to discover, test and make 
available new treatments for existing and emerging threats to health. The reasons for the shift 
to India to conduct trials are often couched in these terms. Much is made of the need for faster 
recruitment, as well as the need for data that enables regional requirements to be met. For some 
diseases, epidemiology requires recruitment from specific regions. More commonly, industry 
sources stress issues of cost: ‘Locations such as India are attractive for these activities due to 
significantly lower costs and a good availability of qualified employees’. But these trials are 
also ‘about’ generating, if possible, massive profits for the companies that get there first, in any 
particular race, according to the logic of capitalist economies (Rajan 2012). They also help to 
open up a market for existing drugs in new markets, through brand recognition. 
India became a new entrant in a highly differentiated, entrepreneurial environment, competing 
for business in the testing of molecules, most of which will not reach the market. Those that do 
are destined for those markets where the largest profits can be made – quintessentially the USA, 
but also Canada, Europe, Japan and Australasia. The overwhelming majority of drugs being 
tested are for chronic conditions common in these post-industrial societies, because these offer 
the highest potential returns to the sponsoring companies. Although some of these – for 
example diabetes, coronary heart disease or some cancers – also have growing numbers of 
Indian sufferers, Indians are not the main focus of this effort. Both globally and in terms of 
research carried out in India, research priorities follow a market logic.3 Once new drugs have 
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been approved and licensed for sale, sufferers in India need health insurance (which covers less 
than 10% of the Indian population), sufficient wealth, or to negotiate complex arrangements to 
get access to free or cheap drugs provided by the originator companies (Ecks 2010). 
The shift of clinical trials into resource-poor settings raises several social, political and ethical 
issues, usefully summarised by a Nuffield Trust committee (Nuffield Council on Bioethics 
2002). On the positive side, conducting trials in India and other developing countries should 
ensure that drugs are safe and effective for their populations, since there may be genetic 
variations that affect how the drug works. But on the down-side, there are many opportunities 
for human rights abuses. Should these activities in the globalised ‘war against disease’ be 
allowed in India if the drugs do not address the health needs of Indians, or become too 
expensive for them to access, or if the context of the trials inevitably recruits participants in 
questionable ways, in which no-one can be held responsible for what has been done to people? 
In the next section I discuss the Indian contexts within which these trials take place, and the 
features that have been identified as potential sources of coercion, whether direct or indirect, 
hidden or visible.  
The Regulation of Clinical Trials in India 
The main claims about why India is different – if not from the rest of the world, at least from 
those countries where clinical trials have developed furthest towards ethical standards being 
applied successfully – are as follows. Firstly, it is claimed that trials conducted in India do not 
face the same stringency in following the rules, so that the data are more likely to be distorted. 
Secondly, critics suggest that the social conditions, or the meaning-contexts, of trials – 
especially trials that involve poor, seriously ill patients – are so different from those envisaged 
by the rules that they cannot ensure that patient interests are protected. Thirdly, there are a 
series of claims about more technical issues, such as the conditions for informed consent in a 
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poorly educated and vulnerable population. Fourthly, people query whether it is ethical to test 
new drugs on a population when the drugs themselves, if approved, will not be available to 
them – or only at prices so high as to rule out any effective access. Other issues – such as 
compensation in cases where the treatment has adverse side-effects – have also been raised. 
Distortion of data 
The work of a CRO is largely a straightforward process of sending a Clinical Research 
Assistant or a field-worker to each research site and verifying that the data recorded for the 
trial actually reflects what happened to the patient enrolled in the trial. Well-known threats to 
the quality of the records include the invention of data; reporting successful treatment when a 
patient did not complete the course, or failed to improve; record irrelevant information; mislay 
specimens and forms; or fail to keep adequate records of informed consent. Internationally, 
there is a perception that Indian trials are more vulnerable to problems of this kind than in the 
USA, for example (Harris 2014). Good Clinical Practice, and its linked regulations, are not as 
well known as in countries with more experience. Some well-publicised pharmaceutical 
scandals have undermined the credibility of results from Indian companies (on Ranbaxy, see 
Eban 2013; on GVK Biosciences, seeEuropean Medicines Agency 2015), even though 
evidence to support this general presumption – that standards are not as closely followed in 
India as elsewhere – is hard to find and may be part of attempts by competitors to gain an 
unwarranted advantage. Many accounts suggest that US FDA monitoring provides reassurance 
that standards are being maintained (Editor 2000: 2177). Commentators often welcome the 
increase in its monitoring that followed the opening of its offices abroad (including in India 
and in China).  
Clearly, all down the chain, throughout the assemblage, all those involved in running a trial 
have a vested interest in having their claims of rigour accepted. In September 2015, for 
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example, the Gujarat FDA called in German and French media for ‘assuaging the fear and 
confusion emanating from the European nations over the quality of the drugs that are 
manufactured in the country after the GVK fiasco’ (Anon. 2015). But these concerns are largely 
to do with documentation rather than with process. Any trial participant might wish to ensure 
that the documentation of their contributions are honestly, accurately and fully recorded, since 
otherwise their participation becomes worthless, as far as the trial is concerned, and they will 
have undertaken risks (of adverse events, of being given a placebo, or an untried and less 
effective new treatment) without even the feeling that others might benefit. 
The social contexts of trials 
There is little regular reporting of the social backgrounds of trial participants (Srinivasan 2009). 
In the civil society critiques, the focus is always on poor, marginalised participants, as in the 
PATH study of HPV vaccines. As far as Phase III and Phase IV trials are concerned, the most 
marginalised people are rarely involved, since they do not even reach the hospitals where the 
trials are conducted. They are more likely to be the ‘healthy volunteers’ needed for Phase I 
trials, since these are normally paid for their participation. As elsewhere, such participants often 
enrol in multiple trials, and the payment s are a major incentive for people near the bottom of 
the social scale, as the few reports available suggest (see, for example, (Hundley 2008b). 
Although public hospitals take part in many Phase II and Phase III trials in the major Indian 
cities, when trials travel to smaller towns they are more likely to have co-investigators from 
private hospitals, whose patient populations are unlikely to include the poorest.  Yet patients 
who are unable to pay the fees for the standard treatment may suddenly be offered free 
treatment, or even to be paid a fee, if they register for a clinical trial (Hundley 2008a). One 
‘selling-point’ for India has been that many patients are ‘treatment-naïve’, i.e. have not already 
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been treated for the disease under investigation, suggesting a preference for those whose 
contact with the health system has been limited. 
Evidence gained from detailed investigations show how far recruitment to some clinical trials 
in India has involved some of the most marginalised and vulnerable people. In Bhopal, from 
2004–2012, they involved those left disabled by methyl isocyanate (MIC) in the gas leak on 
the night of 2–3 December 1984. In the immediate aftermath of this leak, many aspects of the 
disaster were hidden – such as the actual chemical that was released. The inadequacies of the 
local health services were brutally exposed, both in their lamentable responses to the acute 
needs of those who had been poisoned, and in their failure to provide appropriate care for the 
chronic illnesses of those exposed to the gas, and of their children. Over the following years, 
official and private responses were uncoordinated and provided only under considerable 
pressure from NGOs and advocacy groups. Patient record-keeping practices made it difficult 
if not impossible to be sure that survivors’ needs were being taken into account: in Government 
hospitals it was impossible to follow the care of an individual patient, and in private facilities, 
records were given to the patients (Eckerman 2001). The Bhopal Memorial Hospital and 
Research Centre (BMHRC), established in August 2004, was supposed to concern itself 
exclusively with the treatment of gas victims and their families and to carry out research on the 
long-term effects of MIC exposure.  
Yet soon after the BMHRC was opened, drug trials were conducted there for US and Indian 
companies, for various anti-bacterials and anti-coagulants. None, apparently, focused on the 
effects of the gas or took account of the existing multi-drug therapy for treatment of MIC-
related ailments. Only six trials were fully reported to the CDSCO. There were 14 deaths, ten 
of whom were gas victims. Investigations into these deaths were cursory, and no compensation 
has been paid out. The hospital’s Institutional Review Board (IRB) included staff from within 
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the hospital that had direct financial interests in the clinical studies being conducted. Given that 
the hospital is said to have received about $200,000 in fees for these studies, conflicts of interest 
were inevitable. Ethical review before approval was brief and superficial, and informed consent 
was not taken from many of the participants; doctors themselves signed off on the consent 
forms. Questions about all these issues have been left unanswered. The existence of trials like 
this, even if they are uncommon, raises ‘questions about the regulation and approval process 
for the testing, besides bringing the quality of research in India under a cloud’ (Krishnan 2012; 
Lakhani 2011; Varma 2011). 
Informed consent in poorly educated and marginalised populations 
A major focus of concern has been the adequacy of ethical review procedures in situations 
where the social distance between potential trial participants and trial investigators is wide, 
leading to the possibility of abuse of power and privilege to coerce individuals into trials. The 
idea of a placebo, or even that patients may not be receiving their doctor’s preferred treatment, 
may be hard to convey. Financial compensation for taking part may be so substantial that it 
becomes an overwhelming inducement.  
Most Indian clinical trial participants have difficulty to understand what is involved when they 
sign up. They cannot easily recall key features of the trial; the recruiter often frames this 
information with a positive spin, giving little attention to the right to withdraw or about 
alternative therapies; and the delivery of the right amount of information – pitched at a level 
that aids comprehension – is rarely achieved (Siminoff, Caputo and Burant 2004). Examples 
abound. Here is a case in which a man with terminal cancer was enrolled in a trial involving 
head shaving (or not) before his brain surgery: 
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… the consent forms Iqbal signed on his father's behalf were in English, a language he 
neither speaks nor reads. "If they had been in Bengali, I could have followed them," he 
said … (T)he trial had nothing to do with chemo or radiation. It simply tracked the 
infection rate in patients whose heads were not shaved before brain surgery. … "The 
doctor told me shaving heads was the old process, that not shaving is the latest," he said 
as the sunlight faded. "I just told the doctor, 'Do what is good. You are god to me' 
(Hundley 2008b).  
If the language of the researchers is different from the home language by the participants, the 
need to ‘explain the consent form in simple language to the participants’ is made more difficult 
(Bhansali et al. 2009); see also (Joglekar et al. 2013). Problems of ‘therapeutic misconception’ 
– the mistaken belief that entry into a trial will ensure better treatment for the underlying disease 
– are common in almost all settings, not just in India. But the risk of therapeutic misconception 
is considerably enhanced in the absence of effective national health systems. Such 
misconceptions persist despite what appears to be an adequate informed consent process. In 
countries like India, to carry out trials where the alternative to enrolment is not ‘current best 
practice’ but ‘no treatment at all’ or ‘treatment that might be so expensive as to push 
participants into (even more acute) poverty’ is not ethical, but can be considered the result of 
various forms of violence, as I discuss further below.  
In practice, most research protocols in India are drafted in English, and then translated (who 
does this job is not usually revealed, nor if or how they are tested for comprehensibility) and 
many documents remain in English. Rajan describes a company that he terms ‘gold-standard’ 
with a deep and sincere commitment to good clinical practice, one that requires its trial 
participants to be literate, though not in English. Yet the bulletin board in the waiting room 
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with information about the risks involved in taking part in a Phase I trial included only 
documents entirely in English (Rajan 2007: 76-77).  
For a significant minority – in many studies involving Indian participants – information is seen 
as irrelevant, however, because willingness to take part depends on the ‘faith’ or ‘trust’ in a 
medical practitioner. As one interviewee in a north Indian study put it, ‘We’ll only take the 
new agent because doctors are telling us to. If they tell us to take a particular medicine, we will 
surely do so even if it is poisonous’ (DeCosta et al. 2004).  
Some Indian studies suggest that, with care and attention to the translation of documents, to 
the setting within which consent is taken, and to the use of paramedical or other staff rather 
than doctors to transmit the information, reasonably good levels of understanding can be 
achieved even in marginalised groups (Joglekar et al. 2013). But even so, the context is 
radically different from that in which informed consent has been developed as a technology: 
In this part of the world, the potential subject is from a family and community oriented 
culture, his/her normal decision making process involves his/her reference group, and 
exclusion of that group from that process damages the process. Related to this is the 
point that patients from cultures which value or expect paternalism, and place a high 
degree of systematic trust and reliance in the doctor’s expertise, need to have this 
respected in the consent process (DeCosta et al. 2004).  
Ethical Review Committees 
Ethical Review Committees (ERCs) should have as one of their key tasks to prevent any 
coercion – whether structural or symbolic – in the recruitment of participants to clinical trials. 
In practice, membership of ERCs involves long hours, exacting work, an unfeasible workload 
and the threat of hostility from researchers upset by unfavourable decisions (Simpson et al. 
Roger Jeffery: War Against Disease 
 
Page 16 of 34 
 
2015). Many members display enthusiasm when talking about the value of ethical review, and 
are aware of the possibility that, as a Professor of Medical Ethics in the UK describes it, ‘they 
will be merely a moral fig-leaf covering … structural violence’ (Ashcroft 2005). They accept 
that their work is a small response in the face of a much bigger problem, because of the 
pressures to review several trials in a short period of time, with limited training, little or no 
administrative assistance and no chance to verify whether the trials they approve actually 
follow the procedures as promised. ‘Lay’ members working for ‘institutional’ review boards, 
set up by a hospital or medical college to review in-house research proposals, may be selected 
for their pliability; the medical members are vulnerable to pressures from colleagues. 
Independent review committees may be purely commercial in orientation, offering light-touch 
reviews. Sponsors faced with a rigorous review procedure may withdraw a proposal and submit 
it elsewhere, to an ERC where other priorities are important (Hundley 2008a). While some of 
these threats to good practice can be avoided, abuses could slip through the rather coarse net 
set up to hold them back. Since 2012, anecdotal evidence suggests that these committees are 
much more willing to delay the approval of trials when members are not satisfied that they are 
fully ethical. In this respect, they have become in some ways part of the response to reports of 
unethical practice. 
Responses to Reports of Abuses 
The case for an indignant response to the prospect of global clinical trials coming to India was 
made forcefully in 2005 by the editor of Indian MIMS and a colleague, calling them ‘illegal 
and unethical’ and characterising the situation as ‘a new colonialism’ (Nundy and Gulhati 
2005). This moral position is not, however, universal. A CRO conducting trials within India 
justified his work on the grounds that it is time India ‘pulled its weight’ in what he sees, 
apparently, as a necessary evil, or at least morally problematic: 
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The time was when India was dependent on the western population being subject of 
clinical trials. I think we have derived enough medicine from there. I think the argument 
that we are being used as victims of clinical trials – even though you have to take 
extreme view on it – may not necessarily be true because it was happening for decades 
or centuries where people from the west have contributed some of the medicines that 
we are enjoying right now. So it’s time we have to start contributing.  
The PATH/ICMR study with which I began this chapter provides a coda to this argument. The 
‘informed consent’ procedures were badly flawed. A substantial number of those included in 
the trial were girls from Adivasi backgrounds living in hostels, and extra care should have been 
taken beyond that appropriate to the protection of children in general. It is not clear why girls 
living in areas remote from good medical care were selected for the study, rather than a 
balanced spread across social and residential settings, as the internal review committee pointed 
out (Sarojini et al. 2010).  
The 41-member Parliamentary panel … says the implementation of the PATH study in 
both states was flawed. It says serious adverse events were not monitored and consent 
of trial subjects were not taken properly. For instance, many consent forms had only 
thumb impressions, most parents and guardians of the girls were illiterate and 69 out of 
100 forms in Andhra Pradesh bore no signatures of witnesses, which was mandatory 
(Jayaraman 2013).  
Of the approximately 24,000 girls aged 10–14 who received either Merck's Gardasil or 
GlaxoSmithKline's Cervarix vaccine seven girls — five in Andhra Pradesh and two in Gujarat 
— died within a year or so of receiving the vaccines. Only fragmentary evidence was available 
about the causes of these deaths. The official report into the PATH study identified ‘clear 
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violations’ but no action was suggested, with ‘the committee exonerating all involved in the 
project’ (Sarojini et al. 2010): 19.  
One of the defenders of the study expressed perhaps most clearly the lack of empathy between 
the sponsors of such trials and the people undergoing them. Dr Seth Berkley, chief executive 
of the GAVI Alliance, a public-private partnership that is ‘focused on saving children's lives 
and protecting people's health by increasing access to immunisation in poor countries’ wrote: 
India has the largest number of cervical cancer deaths in the world. Suspension of the 
jab will inevitably cost lives. … But perhaps the most compelling evidence is that the 
suicide rate for girls in southern India is one of the highest in the world, with about 32 
of every 100,000 girls killing themselves. With tens of thousands of teenage girls 
receiving the HPV vaccine, it would have been unusual if none of them went on to kill 
themselves (Berkley 2013). 
The Supreme Court ruling discussed at the beginning of this paper prompted a raft of reform 
measures aimed at strengthening protections for Indian clinical trial participants. These 
include: (i) a more rigorous ‘three tier’ committee system for screening clinical trial protocols 
at the DCGI; (ii) three new criteria for evaluating clinical trials, namely (a) assessment of risk 
versus benefit to the patients, (b) innovation vis-à-vis existing therapeutic options and (c) 
unmet medical need in the country; (iii) audio-visual recordings of the informed consent 
process, and: (iv) the mandatory registration of Indian Ethical Review Committees (Choudhury 
and Ghooi 2013; Goyal 2014).  
Most controversial were further rules relating to compensation for clinical trial-related injuries 
or death. Some measures, which aim to strengthen procedural oversight so that incidents are 
investigated properly and compensation paid if appropriate, are in line with international 
approaches. Yet some of the new criteria for compensation depart radically from the regimes 
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in other countries. For example, one provision states that ‘In the case of an injury occurring to 
the clinical trial subject, he or she shall be given free medical management as long as required’ 
(Ghooi 2013). This would seem to apply regardless of whether the trial itself had caused a 
medical problem. Another rule states simply that subjects shall be eligible for compensation 
for ‘use of placebo in a placebo-controlled trial.’ Entitlement to compensation was also 
established for failure of an investigational product to provide the intended therapeutic effect. 
These changes caused serious concerns among trial sponsors about legal and financial risks 
and led to an exodus of clinical trials from India. The numbers of clinical trials approved by 
CDSCO fell from 500 in 2010 to just 107 in 2013. Sponsors and CROs shifted their activities 
to ‘rival’ countries with more favourable regulatory systems. Alarmed by the impact on its 
clinical trial industry, the Indian government watered down some of the reform measures for 
compensation and for audio-visual recording of consent procedures. The CEO of Quintiles, a 
major global CRO, said in April 2016 that its concerns over open-ended responsibility to 
compensate trial participants (or their families) for all adverse events and deaths have been ‘set 
at rest’ (Das & John, 2016). Furthermore, in January 2015, and in line with the Modi 
government’s pro-business strategy, the Ministry of Health has proposed ‘pre-submission 
meetings’ between drug regulators and stakeholders in order to increase efficiency and speed 
up approval times (Nair 2015). It remains to be seen whether the efforts to entice business back 
to India can be made compatible with the enhanced protections for Indian trial participants that 
is – rightly – demanded by advocacy groups in civil society, Parliament, and the Supreme 
Court. 
Violence: structural and symbolic 
Violence enters into discussions of the ethics of clinical trials when considering the possible 
risks of sick or otherwise vulnerable people being coerced into taking part. Well-known 
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historical examples reveal that participants often had little or no choice – most obviously, those 
in prisons of one kind or another. The ethical codes that I describe below therefore attempt to 
ensure that individuals who are approached to join a clinical trial are in a position to make a 
voluntary choice about whether or not to be involved. This principle has become 
institutionalised as informed consent: the provision of adequate information, usually in written 
form, but often supplemented orally, to ensure that the choices made by potential participants 
are not based on false claims about either the costs or the benefits of taking part. Those running 
trials are expected to provide this information in a form that allows for the trial’s implications 
to be easily understood.  
As it stands, this ‘ethical codes’ approach is vulnerable to the criticism that it fails to locate the 
relationships between researchers and researched in the wider social, political and economic 
contexts within which such interactions take place. In other words, such an approach is framed 
around the idea that those conducting the research, and those being asked to participate in it, 
exist in a free-floating world of the liberal ideal ‘individual’. In this perspective, the problems 
associated with clinical trial management are about the ethics of individual motivation and 
behaviour of those requesting informed consent. The solutions tend to be sought in Standard 
Operating Procedures (SOPs), protocols and documentation. Morality, not politics, is the focus.   
With respect to clinical trials there are two main kinds of critique of this position. The first 
identifies within clinical trials ‘structural violence’, in non-Marxist and Marxist versions. I take 
Jill Fisher as the main proponent of a non-Marxist position and Kaushik Sunder Rajan as 
representative of an explicitly Marxist position. The second critique, which is less well-
developed in this field, considers ‘symbolic violence’, starting from discussions by Pierre 
Bourdieu. 
Structural Violence: Non-Marxist Approaches 
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Paul Farmer defines structural violence in terms of ‘social arrangements that put individuals 
and populations in harm’s way’ that are ‘embedded in the political and economic 
organization of our social world; they are violent because they cause injury to people’. 
Individual agency is not the issue. ‘Structural violence is visited upon all those whose social 
status denies them access to the fruits of scientific and social progress’ (Farmer 2001: 79), 
drawing on his experience as both a public health doctor and an anthropologist in Haiti (see, 
for example, Das et al. 2009; Farmer 1996; Farmer 2001; Farmer 2004; Farmer 2005). The 
term ‘structural violence’ has a pedigree at least as far back as the work of Johan Galtung 
(1969) and has links to the work of liberation theologians (Farmer 2004: 307). Victims 
become so by virtue of their location in social and geographical terms, as members of 
minority groups or those marginalised or excluded from reaching their full potential because, 
for example, of their race, class, gender, ethnicity, religious group membership or sexual 
orientation. 
In public health the term provides a call to action over the inequalities that can be observed in 
epidemiological data: if mortality or morbidity rates are higher in some populations than in 
others, then these differences can be ascribed to the social structures which work themselves 
out ‘behind the scenes’.  
Jill Fisher uses the concept of structural violence when she argues that ‘informed consent’ in 
clinical trials rests on unexamined notions of the dyad of researcher-researched, understood as 
free-floating individuals. ‘The influences of larger social, cultural, economic and/or political 
realities are almost extraneous within this rubric’ (Fisher 2013: 356).  Because ‘the threat or 
risk of harm stemming from a society rife with inequalities acts as a source of structural 
coercion for individuals,’ (Fisher 2013: 363-4) she argues for attention to be paid to the ‘lived 
experiences of research participants’ (Fisher 2013: 356). Even in the best cases, amongst a 
well-informed population, ‘the process of informed consent in research often nonetheless fails 
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to achieve its purported ends’ (Fisher 2013: 369) because potential participants are enmeshed 
in webs of structural violence that they carry with them into the clinic or the laboratory. The 
inadequacies of informed consent are even more likely to be the case where inequalities are 
steeper, potential participants are poorer, and where they have little access to alternative, 
affordable, and available health care options. In such circumstances – typical of India – 
‘informed consent’ may act more to protect the researchers from claims for damage incurred 
during the trial, than to protect the human rights of the trial participants. 
Structural Violence: Marxist Approaches 
Kaushik Sunder Rajan takes a Marxist view of structural violence, linking the structural 
violence involved in clinical trials directly to the production of value in capitalist societies. 
Appeals to the moral or ethical probity of individual researchers are inadequate: 
Even if all clinical trials conducted in India or other Third World countries adhered to 
the letter of the law and the spirit of ethical codes, the very structure of this network [of 
economic and social relations] would remain one of exploitation (Rajan 2007: 67). 
More recently he has analysed ‘bio-capital’ starting, as Marx does, with value. Rajan suggests 
that the various crises facing global pharmaceutical economies affect research-and-
development based pharmaceutical companies and also the Indian generics drugs industry as 
they attempt to realise value from the bodies of patients (Rajan 2012: 321). For Rajan, the 
structure behind structural violence is a capitalist one, one that is recurrently in crisis. The 
economy of manufacturing and sale of therapeutic molecules depends on an economy of 
research and development (the current need, for example, to abandon the search for ‘block-
buster’ drugs and to orient towards personalised medicines). These two economies link to the 
economy of clinical trials, more and more autonomous, that creates new forms of labour 
amongst experimental subjects (usually male) as well as among employees (usually female) of 
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contract research organisations. These three economies link to an economy of health, that is, to 
the appropriation of health by capital (Rajan 2012: 335-37). In this context he acknowledges 
the difficulty of arguing ‘for therapeutic access to essential medicines for those who need it 
while critiquing economies of therapeutic excess and saturation’ (Rajan 2012: 337). The moral 
critique Rajan implies is that access to people’s bodies for the necessary testing of new or 
altered drugs is acceptable if and only if it does not involve the bodies of ‘previously 
marginalized or dispossessed … subject populations for medical research’ (Rajan 2012: 336) 
The term ‘structural violence’ is obviously attractive, since it offers the possibility of thinking 
about how ‘poverty, hunger, subordination, and social exclusion’ (Farmer 2001: 79) can be 
included within the term of violence. But those who adopt the perspective of structural violence 
have been cogently criticised. The term is too general, and it is hard to adapt its use to cover 
the variety of ‘forms of injustice, their intersections, and the ways in which they are 
compounded’ (Winter 2012): 195). Its broad-brush approach puts all kinds of constraints into 
a single category. It is unclear over whether such violence is hidden or visible, and it provides 
for little more than the use of ‘weapons of the weak’ to challenge it (Scott 1985). Outside the 
field of a politicised public health, the concept of structural violence has fallen into disuse. The 
concept’s moral tone can seem to implicate all those who benefit from the status quo and do 
not act to mitigate its effects on those who are victims of it (Gupta 2012) (Bourgois and 
Scheper-Hughes 2004; Wacquant 2004). It also draws attention away from the visible physical 
violence suffered by those who are affected by various kinds of structurally-based damage 
(Bourgois and Scheper-Hughes 2004).  
Thus, particularly in the form in which it has been used by Rajan, it allows too little scope for 
collective social action to transform those relationships. Can the work of Bourdieu provide a 
more fruitful approach? 
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Symbolic violence 
For Pierre Bourdieu, symbolic violence is at work when the most powerful groups in any 
society naturalise their domination. A given social order reproduces itself through processes of 
misrecognition, ‘the representations of legitimacy [that make possible] the exercise of power’ 
(Bourdieu and Passeron 1977: 5). Bourdieu effects a conceptual shift ‘from ideology to 
symbolic violence’ (Wacquant 2013: 278). Misrecognition (méconnaissance) is neither a 
passive process, nor necessarily the result of conscious efforts to hide what is going on. Rather, 
it is the outcome of multi-level struggles which frame how economic capital is linked to other 
kinds of capital – symbolic, cultural, and social – and the fields within which these struggles 
take place. Misrecognition ‘embodies a set of active social processes that anchor taken-for-
granted assumptions into the realm of social life and, crucially, that … are born in the midst of 
culture’ (Navarro 2006: 19). 
What Bourdieu’s approach does is to focus on the social fields in which domination takes place 
and where it can be contested. It thus provides for spaces in which conflicts appear to set the 
dominated against the dominant: they are 
internecine battles pitting the different sectors of the field of power, that is, different 
fractions of a putative ruling class whose imperium is rendered both more opaque and 
more impregnable by the growing intricacy and contradictions internal to the mesh of 
domination (Wacquant 2013: 278).   
This shift matters both theoretically and practically. The analyses of structural violence tend to 
have an air of fatalism about them: structures are powerful, and responses to them can be little 
more than token ones. If one form of structural violence – such as social marginalisation – is 
overcome, or reduced, another is sure to take its place. By contrast, Bourdieu’s approach allows 
much more for the kinds of struggles that have been taking place in India.  Different actors 
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relating to the field of the clinical trial have come publicly into conflict in real and significant 
ways, as the opening story of the PATH study makes clear. Misrepresentations can be 
challenged. Practical proposals can have visible effects. For example, the existing lack of 
common ground between CRO staff and marginalised participants in India has often been 
commented on (Srinivasan 2009)., and this may make it more likely that trial participants may 
misperceive their participation as better treatment. It may be possible to enhance understanding 
if explanations are given to groups as well as to individuals, and if innovative visual aids are 
used (Sastry et al. 2004), though this finding has been challenged (Sarkar et al. 2010). But some 
trial participants are only too aware of both their relatively powerless position and the symbolic 
violence through which they have been persuaded to take part in a trial: 
“Of course I'm angry. I've been angry ever since I found out," Mr Shrivastave said. "But 
what can I do? We are poor people. If I had money I would have filed a case against 
them straight away, but we don't have money. If I'd known it was a drug trial I never 
would have agreed. How can I ever trust them again? These people should do trials on 
their own families, not poor people like me.” (Lakhani 2011)  
This awareness does not stand on its own: within India there are civil society organisations 
prepared to channel it into action, and powerful institutions at the helm of Indian society – the 
Supreme Court and Parliament, in this case – prepared to go into battle. Following Bourdieu, 
then, and considering symbolic violence as a set of misrepresentations, we can situate the field 
of clinical trials as a site for inter- and intra-elite contestations, and understand better the strong 
civil society, parliamentary and judicial responses to perceived infractions of the human rights 
of trial participants after 2010. But the Indian contestations do not occur in a vacuum, but are 
located in a field set by the particular form that global bio-medicine has taken, especially in the 
past 20 years – but also drawing on a much longer history of conflict and negotiation over 
ethics and trial procedures. 
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Conclusion 
The issues highlighted by these contestations are several. There are still considerable 
opportunities for trial participants to be recruited in ways that – despite the researchers 
following the rule-book – can involve playing on their vulnerabilities, leaving them ill-
informed, and without protection if anything goes wrong. Such challenges are not restricted to 
trials carried out as part of international collaborations, though such studies may be less likely 
to be drafted in ways that are compatible with ideas of national benefit (e.g. post-trial access to 
drugs). Yet it is clear that, despite the pressures that were brought to bear by the global 
pharmaceutical and clinical trial assemblage, India’s vibrant civil, political and judicial society 
has managed to establish protections for trial participants that did not exist before 2012.  
These changes suggest that the dichotomous approaches of Farmer and Rajan – essentially 
positing structural forces that are unchanging and hard to affect, and that determine and require 
structural violence – are not nuanced enough. Bourdieu’s focus on symbolic violence, the 
ability of people to misrepresent their subjugation and embrace it, but also – often with the help 
of others – to see through this misrepresentation, as a result of intra- and inter-elite conflicts, 
is much more helpful. Such an approach makes political effort potentially the basis for shifts, 
to allow new social forms to come into being, even if the process is slow and fraught with the 
possibility of sliding backwards. In policy terms, this suggests that state regulation is not 
enough: to give meaning to the rules needs civil society organisations with a watching brief, 
able to raise concerns and to alert the regulators – directly or through the media – of abuses. 
Ethical review committees cannot play this role on their own, nor can international monitors. 
The ability to think differently about ‘the trial’ and what it might mean to those who might take 
part in it, is a crucial outcome of struggle.  
In sum, the new situation requires political action to empower those urging more concern for 
ethical considerations to be taken seriously, and better regulatory frameworks to monitor the 
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relationships within which trials are conducted. The struggle to work out how best to mitigate 
the remaining ‘symbolic violence’ is worthwhile, even if how this might be done remains 
unclear as yet. In addition – and here, structural violence is helpful – the surrounding context 
of inequality and systematic marginalisation means that removing all forms of subtle, hidden 
or visible coercion is highly unlikely. The effort has only just started: and it may not last. We 
cannot be sanguine about the outcome. 
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